FIGO stage IIIC endometrial carcinoma: Resection of macroscopic nodal disease and other determinants of survival

International Journal of Gynecological Cancer

Volumn 13, Issue 5, 2003, Pages 664-672

  Bristow, Robert E ^a   Zahurak, M L ^b   Alexander, C J ^a   Zellars, R C ^a   Montz, F J ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Chemotherapy; Lymphadenopathy; Radiation therapy; Surgery

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; DISEASE SPECIFIC SURVIVAL; ENDOMETRIUM CARCINOMA; FEMALE; FIGO STAGING; HUMAN; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MINIMAL RESIDUAL DISEASE; PARAAORTIC LYMPH NODE; PELVIS LYMPH NODE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS;

ADENOCARCINOMA, CLEAR CELL; ADULT; AGED; AORTA, THORACIC; CARCINOMA, ENDOMETRIOID; COMBINED MODALITY THERAPY; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MARYLAND; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PELVIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS;

EID: 1242269313     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2003.13385.x     Document Type: Article

References (47)

1. Jemal A, Thomas A, Murray T, Thun M. Cancer Statistics, 2002. CA Cancer J Clin 2002;52:23-47.
2. Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer. Cancer 1987;60:2035-41.
3. Kadar N, Homesley HD, Malfetano JH. Prognostic factors in surgical Stage III and IV carcinoma of the endometrium. Obstet Gynecol 1994;84:983-6.
4. Chuang L, Burke TW, Tornos C et al. Staging laparotomy for endometrial carcinoma. Assessment of retroperitoneal lymph nodes. Gynecol Oncol 1995;58:189-93.
5. Ayhan A, Tuncer S, Tuncer R, Yüce K, Kücükali T. Tumor status of lymph nodes in early endometrial cancer in relation to lymph node size. Eur J Obstet Gynecol 1995;60:61.
6. Hiratake K, Hareyama H, Sakuragi N, Nishiya M, Makinoda S, Fujimoto S. A clinical and pathologic study on para-aortic lymph node metastasis in endometrial carcinoma. J Surg Oncol 1997;65:82-7.
7. Nelson G, Randall M, Sutton G, Moore D, Hurteau J, Look K. FIGO stage IIIC endometrial carcinoma with metastases confined to pelvic lymph nodes. Analysis of treatment outcomes, prognostic variables, and failure patterns following adjuvant radiation therapy. Gynecol Oncol 1999;75:211-4.
8. Mundt AJ, Murphy KT, Rotmensch J, Waggoner SE, Yamada SD, Connell PP. Surgery and postoperative radiation therapy in FIGO Stage IIIC endometrial carcinoma. Int J Radiat Oncol Biol Phys 2001;50:1154-60.
9. McMeekin DS, Lashbrook D, Gold M, Johnson G, Walker JL, Mannel R. Analysis of FIGO Stage IIIC endometrial cancer patients. Gynecol Oncol 2001;81:273-8.
10. Sheperd JH. Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol 1989;96:889-92.
11. Anonymous. Corpus uteri. In: American Joint Committee on Cancer: AJCC Cancer Staging Manual. Philadelphia: Lippincott-Raven, 5th edn, 1997;195-200.
12. Feuer G, Calanog A. Endometrial carcinoma. Treatment of positive para-aortic nodes. Gynecol Oncol 1987;27:104-9.
13. Hicks ML, Piver MS, Puretz JL et al. Survival in patients with paraaortic lymph node metastases from endometrial adenocarcinoma clinically limited to the uterus. Int J Radiat Oncol Biol Phys 1993;26:607-11.
14. Potish RA, Twiggs LB, Adcock LL, Savage JE, Levitt SH, Prem KA. Paraaortic lymph node radiotherapy in cancer of the uterine corpus. Obstet Gynecol 1985;65:251-6.
15. Rose PG, Cha SD, Tak WK, Fitzgerald T, Reale F, Hunter RE. Radiation therapy for surgically proven para-aortic node metastasis in endometrial carcinoma. Int J Radiat Oncol Biol Phys 1992;24:229-33.
16. Schorge JO, Molpus KL, Goodman A, Nikrui N, Fuller AF. The effect of postsurgical therapy on Stage III endometrial carcinoma. Gynecol Oncol 1996;63:34-9.
17. Melfi C, Holleman E, Arthur D, Katz B. Selecting a patient characteristics index for prediction of medical outcomes using administrative claims data. J Clin Epidemiol 1995;48:917-26.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-80.
19. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Nat Cancer Inst 1959;22:719-48.
20. Cox DR. The Analysis of Binary Data. London: Methuen, 1970.
21. SAS Institute Inc. SAS. User's Guide: Statistics, Version 5. Cary, NC: SAS Institute Inc, 1985.
22. Statistics and Epidemiology Research Corporation. EGRET User's Manual. Seattle, WA: Statistics and Epidemiology Reseach Corporation, 1988.
23. Boronow RC, Morrow CP, Creasman WT et al. Surgical staging in endometrial cancer. Clinical-pathologic findings of a prospective study. Obstet Gynecol 1984;63: 825-32.
24. Corn BW, Lanciano RM, Greven KM et al. Endometrial cancer with para-aortic adenopathy. patterns of failure and opportunities for cure. Int J Radiat Oncol Biol Phys 1992;24:223-7.
25. Spirtos NM, Gross GM, Freddo JL, Ballon SC. Cytoreductive surgery in advanced epithelial cancer of the ovary: The impact of aortic and pelvic lymphadenectomy. Gynecol Oncol 1995;56:345-52.
26. Potish RA, Downey GO, Adcock LL, Prem KA, Twiggs LB. The role of surgical debulking in cancer of the uterine cervix. Int J Radiat Oncol Biol Phys 1989;17:979-84.
27. Hacker NF, Wain GV, Nicklin JL. Resection of bulky positive lymph nodes in patients with cervical carcinoma. Int J Gynecol Cancer 1995;5:250-6.
28. Cosin JA, Fowler JM, Chen MD, Paley PJ, Carson LF, Twiggs LB. Pretreatment surgical staging of patients with cervical carcinoma: the case for lymph node debulking. Cancer 1998;82:2241-8.
29. Onda T, Yoshikawa H, Mizutani K et al. Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy, and radiation therapy. Br. J Cancer 1997;75:1836-41.
30. Mariani A, Webb MJ, Galli L, Podratz KC. Potential therapeutic role of para-aortic lymphadenectomy in node-positive endometrial cancer. Gynecol Oncol 2000;76:348-56.
31. Larson DM, Broste SK, Krawisz BR. Surgery without radiotherapy for primary treatment of endometrial cancer. Obstet Gynecol 1998;91:355-9.
32. Katz LA, Andrews SJ, Fanning J. Survival after multimodality treatment for Stage IIIC endometrial cancer. Am J Obstet Gynecol 2001;184:1071-3.
33. Bristow RE, Zerbe MJ, Rosenshein NB, Grumbine FC, Montz FJ. Stage IVB endometrial carcinoma. The role of cytoreductive surgery and determinants of survival. Gynecol Oncol 2000;78:85-91.
34. Goff BA, Goodman A, Muntz HG, Fuller AF, Nikrui N, Rice LW. Surgical stage IV endometrial carcinoma. A study of 47 cases. Gynecol Oncol 1994;52:237-40.
35. Greer BE, Hamberger AD. Treatment of intraperitoneal metastatic adenocarcinoma of the endometrium by the whole-abdomen moving strip technique and pelvic boost irradiation. Gynecol Oncol 1983;16:365-73.
36. Chi DS, Welshinger M, Venkatraman ES, Barakat RR. The role of surgical cytoreduction in Stage IV endometrial carcinoma. Gynecol Oncol 1997;67:56-60.
37. Scarabelli C, Campugnutta E, Giorda G et al. Maximal cytoreductive surgery as a reasonable therapeutic alternative for recurrent endometrial carcinoma. Gynecol Oncol 1998;70:90-3.
38. Smith MR, Peters WA, Drescher CW. Cisplatin, doxorubicin hydrochloride, and cyclophosphamide followed by radiotherapy in high-risk endometrial carcinoma. Am J Obstet Gynecol 1994;170:1677-81.
39. Aoki Y, Kase H, Watanabe M, Sato T, Kurata H, Tanaka K. Stage III endometrial cancer. Analysis of prognostic factors and failure patterns after adjuvant chemotherapy. Gynecol Oncol 2001;83:1-5.
40. Connell PP, Rotmensch J, Waggoner S, Mundt AJ. The significance of adnexal involvement in endometrial carcinoma. Gynecol Oncol 1999;74:74-9.
41. Mackillop WJ, Pringle JF. Stage III endometrial carcinoma. Cancer 1985;56:2519-23.
42. Behbakht K, Yordan EL, Casey C et al. Prognostic indicators of survival in advanced endometrial cancer. Gynecol Oncol 1994;55:363-7.
43. Ashman JB, Connell PP, Yamada D, Rotmensch J, Waggoner SE, Mundt AJ. Outcome of endometrial carcinoma patients with involvement of the uterine serosa. Gynecol Oncol 2001;82:338-43.
44. Fleming GF, Fowler JM, Waggoner SE et al. Phase I trial of escalating doses of paclitaxel combined with fixed doses of cisplatin and doxorubicin advanced endometrial cancer and other gynecologic malignancies: a Gynecologic Oncology Group study. J Clin Oncol 2001;19:1021-9.
45. Thigpen T, Blessing J, Homesley H et al. Phase III trial of doxorubicin ± cisplatin in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group (GOG) study. Proc Am Soc Clin Oncol 1993;12:261 (Abstract 830).
46. Aapro M, Bolis G, Chevallier B et al. An EORTC-GCCG randomized phase II trial of doxorubicin (dox) versus dox-cisplatin (CDDP) in endometrial carcinoma. Proc Am Soc Clin Oncol 1994;13:275 (Abstract 885).
47. Ball HG, Blessing JA, Lentz SS et al. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1996;62:278-81.